Suppr超能文献

正性肌力药物的致心律失常潜能

Arrhythmogenic potential of positive inotropic agents.

作者信息

Stump G L, Wallace A A, Gilberto D B, Gehret J R, Lynch J J

机构信息

Department of Pharmacology, Merck Research Laboratories, West Point, PA 19486, USA.

出版信息

Basic Res Cardiol. 2000 Jun;95(3):186-98. doi: 10.1007/s003950050181.

Abstract

The clinical use of positive inotropic agents has been associated with increased mortality, with proarrhythmia speculated to be a contributing factor. This study compares the arrhythmogenic potentials of six positive inotropic agents representing different mechanistic classes: the beta-adrenergic agonist dobutamine, the adenylyl cyclase activator forskolin, the phosphodiesterase-III inhibitor milrinone, the cardiac glycoside ouabain, and the sodium channel agonists DPI 201-106 and BDF 9148. These agents were studied in dogs with anterior myocardial infarction using lower and higher dose i.v. regimens targeted to elicit 20-40% and 70-90% increases in LV+dP/dt, respectively. Precipitation of new ventricular arrhythmia by programmed ventricular stimulation was observed in all treatment groups. Incidences of new arrhythmia were comparable in the lower dose regimens, ranging from 16.7% (3/18 animals with BDF 9148) to 31.6% (6/19 animals with DPI 201-106), and in the higher dose regimens, ranging from 10.0% (1/10 animals with milrinone) to 27.7% (5/18 animals with DPI 201-106). The overall incidence of new ventricular arrhythmia ranged from 27.3% (3/11 animals with ouabain) to 47.4% (9/19 animals with DPI 201-106). No differences were observed in underlying infarct size or time from infarction to electrophysiologic study between subgroups of animals in which new arrhythmias were precipitated vs. those remaining non-responsive in any treatment group. The positive inotropic agents tested displayed diverse total group effects on heart rate, electrocardiographic intervals including QTc and ventricular refractoriness. Within individual treatment comparisons revealed a general but not universal pattern of greater ventricular refractory period values in newly inducible vs. non-inducible subgroups in the DPI 201-106, BDF 9148 and ouabain (low and high dose); milrinone and dobutamine (high dose) treatment groups. These findings indicate that regardless of underlying cellular mechanism of action, the six positive inotropic agents tested all displayed comparable proarrhythmic potentials unrelated to underlying infarct size and time from infarction. This observation suggests the general shared property of increased myocardial contractility, potentially adversely affecting myocardial oxygen balance, myocardial perfusion and electrical stability in the setting of previous myocardial infarction, to be a common underlying cause for arrhythmogenesis. Additionally, alterations in ventricular refractoriness and repolarization may contribute significantly to proarrhythmia with some positive inotropic interventions.

摘要

正性肌力药物的临床应用与死亡率增加相关,推测心律失常是一个促成因素。本研究比较了六种代表不同作用机制类别的正性肌力药物的致心律失常潜力:β-肾上腺素能激动剂多巴酚丁胺、腺苷酸环化酶激活剂福斯高林、磷酸二酯酶III抑制剂米力农、强心苷哇巴因以及钠通道激动剂DPI 201-106和BDF 9148。在患有前壁心肌梗死的犬中,采用较低和较高剂量的静脉给药方案对这些药物进行研究,较低剂量方案旨在使左心室 +dP/dt分别增加20 - 40%,较高剂量方案旨在使其增加70 - 90%。通过程序性心室刺激诱发新的室性心律失常在所有治疗组中均有观察到。在较低剂量方案中,新心律失常的发生率相当,范围从16.7%(BDF 9148组18只动物中的3只)到31.6%(DPI 201-106组19只动物中的6只);在较高剂量方案中,范围从10.0%(米力农组10只动物中的1只)到27.7%(DPI 201-106组18只动物中的5只)。新室性心律失常的总体发生率范围从27.3%(哇巴因组11只动物中的3只)到47.4%(DPI 201-106组19只动物中的9只)。在任何治疗组中,诱发新心律失常的动物亚组与仍无反应的动物亚组之间,在基础梗死面积或从梗死到电生理研究的时间方面均未观察到差异。所测试的正性肌力药物对心率、包括QTc在内的心电图间期以及心室不应期显示出不同的总体组效应。在个体治疗比较中发现,在DPI 201-106、BDF 9148和哇巴因(低剂量和高剂量);米力农和多巴酚丁胺(高剂量)治疗组中,新可诱导亚组与不可诱导亚组相比,心室不应期值普遍但并非普遍存在更大的模式。这些发现表明,无论潜在的细胞作用机制如何,所测试的六种正性肌力药物均显示出相当的致心律失常潜力,与基础梗死面积和梗死时间无关。这一观察结果表明,增加心肌收缩力这一普遍的共同特性,可能会对既往心肌梗死情况下的心肌氧平衡、心肌灌注和电稳定性产生不利影响,是心律失常发生的一个共同潜在原因。此外,心室不应期和复极化的改变可能在一些正性肌力干预中对致心律失常作用有显著贡献。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验